ArticleInternational dental journal2026
Crotonylation and the Risk of Head and Neck Cancer: Insights from a Two-Sample Mendelian Randomization Study.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck cancer (HNC) remains a major global health burden with limited improvement in survival. Crotonylation has been implicated in tumour biology, but its causal contribution to HNC risk is unclear.
methodsWe conducted a two-sample Mendelian randomization (MR) study using expression quantitative trait loci (eQTL)-instrumented expression of crotonylation-related genes. Differential expression was assessed in The Cancer Genome Atlas (TCGA). Mediation MR evaluated 1,400 metabolites and 731 immune-cell traits. Single-cell RNA sequencing (scRNA-seq) mapped cell type - specific expression, and quantitative PCR (qPCR) validated expression in tumour versus normal tissues.
resultsMR analysis identified that genetically predicted expression of Glutaryl-CoA Dehydrogenase (GCDH) and Acyl-CoA synthetase, short-chain family member 2 (ACSS2) were causally associated with an increased risk of HNC, and Double PHD fingers 2 (DPF2) and Histone deacetylase 7 (HDAC7) were found to have protective effects against HNC. Moreover, TCGA analysis confirmed a consistent association between GCDH and HNC risk. Mediation MR showed no significant metabolite mediators, although 16α-hydroxy DHEA 3-sulfate levels exhibited a borderline signal. In contrast, two immune-cell traits: CX3CR1 on CD14⁺CD16⁺ monocytes and CD8 on CD39⁺ CD8^br cells partially mediated the effect of GCDH on HNC. scRNA-seq demonstrated lineage-dependent expression of GCDH, and GCDH was enriched in malignant and stromal compartments, with qPCR confirming elevated GCDH expression in tumour samples compared with adjacent normal tissues.
conclusionThis study suggests a potential causal association between GCDH expression and increased HNC risk, partially mediated by immune-cell traits, pending further validation via colocalization and functional assays. Our findings highlight GCDH as a promising target for further mechanistic studies and potential therapeutic intervention in HNC. CLINICAL RELEVANCE: The identification of GCDH as a potential risk factor in HNC opens new avenues for targeted therapies, offering potential improvements in patient outcomes through precision medicine approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.